Deliverect vs ArkeaBio

Side-by-side comparison of AI visibility scores, market position, and capabilities

Deliverect

LeaderRestaurant Tech

Delivery Order Management

Ghent Belgium delivery order management platform; integrates DoorDash, Uber Eats, and others into restaurant POS systems; raised $240M+; serves 50,000+ locations globally.

About

Deliverect is a delivery order management platform headquartered in Ghent, Belgium. Founded in 2018, the company has raised over $240M in funding and grown to serve more than 50,000 restaurant and food service locations across more than 40 countries. Deliverect solves a critical operational problem for restaurants: as online food delivery has fragmented across dozens of platforms, restaurants must manage orders from DoorDash, Uber Eats, Grubhub, Just Eat, Deliveroo, and others separately, leading to tablet sprawl, manual re-entry errors, and operational chaos.\n\nDeliverect's platform aggregates orders from all connected delivery platforms into a single stream that routes directly into the restaurant's existing POS system. This eliminates the need for dedicated tablets per delivery platform and ensures that orders flow through standard kitchen workflows without manual re-entry. Deliverect also provides menu management tools that allow operators to update menu items, prices, and availability across all delivery platforms simultaneously from a single dashboard.\n\nDeliverect competes with Otter, ItsaCheckmate, and Omnivore in the order aggregation space but has grown to be the clear market leader through its global platform coverage, breadth of delivery and POS integrations, and aggressive international expansion. The company's focus on enterprise restaurant chains and multi-unit operators has driven large contracts with global QSR brands. Deliverect has also expanded into pickup and table ordering channels, positioning itself as a central digital ordering hub for restaurants of all types.

Full profile

ArkeaBio

EmergingAgTech

Livestock Biotech (Methane Reduction)

$40M+ total raised including $26.5M Series A. 2026-27 cattle field trials underway. Backed by Breakthrough Energy Ventures. Only company with a cattle methane vaccine in active trials.

About

ArkeaBio is developing a vaccine that reduces methane emissions from cattle and sheep by targeting the methanogenic archaea (ancient microorganisms) that produce methane in ruminant digestive systems. The company has raised $40 million+ including a $26.5 million Series A, backed by Breakthrough Energy Ventures and Gates Foundation-aligned capital, and has active cattle field trials underway in 2026-2027 — making it the only company with a livestock methane vaccine at this stage of clinical development.

Full profile

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.